# Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Canonical URL: https://biopharmsignal.com/news/REPL/replimune-presents-final-first-in-human-data-for-rp2-in-advanced-solid-tumors-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting
Ticker: REPL
Company: Replimune Group
Source: Replimune Group
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.replimune.com
## Summary

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with

## Article Body
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with
## Recent Company News
- 2026-06-29 12:00 EST — [Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-end-2026-financial-results-and--829c51fd) — Source: Replimune Group
- 2026-06-26 12:00 EST — [Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma](https://biopharmsignal.com/news/REPL/replimune-announces-fda-acceptance-of-rp1-biologics-license-application-resubmis-9ba52bee) — Source: Replimune Group
- 2026-06-25 13:46 EST — [Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/REPL/replimune-presents-final-first-in-human-data-for-rp2-in-advanced-solid-tumors-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting) — Source: Replimune Group
- 2026-06-25 13:46 EST — [Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/REPL/replimune-presents-3-year-landmark-overall-survival-analysis-from-ignyte-clinical-trial-during-oral-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting) — Source: Replimune Group
- 2026-06-25 13:46 EST — [Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA](https://biopharmsignal.com/news/REPL/replimune-announces-planned-rp1-bla-resubmission-following-productive-discussion-with-fda) — Source: Replimune Group
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)